Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
This research study is looking at a new medicine called mRNA-3927 for a rare genetic condition called Propionic Acidemia (PA). The main goals are to check if the medicine is safe and how well people tolerate it. We also want to see if it helps improve the condition by looking at certain markers in the body. The study will happen in three main parts: first, finding the best dose for people aged one year and older; then, testing that dose more thoroughly in a larger group of people aged one year and older to understand its effectiveness; and finally, testing the medicine in babies under one year old. Participants will be carefully monitored throughout the study.
En un coup d'œil
De quoi parle cette étude ?
This study is about a new medicine called mRNA-3927 for a rare genetic condition called Propionic Acidemia, often shortened to PA. People with PA have trouble breaking down certain proteins and fats, which can lead to a build-up of harmful substances in the body. This can cause serious health problems, especially during metabolic crises.
The main goal of this research is to see if mRNA-3927 can help people with PA. We'll be looking carefully at how safe the medicine is and if it's well-tolerated by the body. We also want to understand how it works and whether it can improve the condition. Scientists will measure certain markers in the body to see if the medicine is having a positive effect. Ultimately, this study aims to find the right amount of medicine (the dose) that works best and is safest for patients.
This study is divided into three parts. The first part focuses on finding a safe and effective dose for people aged one year and older. Once we've found a good dose, the second part will involve more people from this age group to really understand how well the medicine works and its safety over a longer period. The third part of the study will then look at the safety and effects of mRNA-3927 specifically in babies who are less than one year old.
Points clés
- This study is testing a promising new medicine for Propionic Acidemia.
- It aims to find a safe and effective dose for a range of ages, from infants to adults.
- Participants will be closely monitored for safety and how well the medicine works.
- Participation involves observation, treatment with mRNA-3927, and follow-up.
- Joining could help advance understanding and treatment of Propionic Acidemia.
Qui peut être éligible ?
To join this study, participants must have a confirmed diagnosis of Propionic Acidemia, which means it has been identified through a genetic test. For the first two people joining the study, they need to be at least 8 years old. After that, anyone joining must be at least 1 year old.
For babies under one year old, they can participate if they were identified with PA through newborn screening or have symptoms and a sibling with PA. They must also weigh at least 3 kilograms (about 6.6 pounds) and have had at least one PA-related health event, such as vomiting, not feeding well, breathing difficulties, or specific blood test abnormalities like metabolic acidosis or high ammonia levels.
Certain conditions would prevent someone from joining the study. This includes any other health issues that, in the doctor's opinion, might make it difficult to understand the study results, or other specific health problems identified during the initial checks.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Do I have a confirmed diagnosis of Propionic Acidemia?
- Am I at least 1 year old, or an infant under 1 year with specific health events?
- Have I had a genetic test that confirms my Propionic Acidemia diagnosis?
- Am I generally healthy enough to participate, without other significant medical conditions?
- If under 1 year, do I weigh at least 3 kilograms and have I had a PA-related health event?
En quoi consiste la participation ?
If you join the study, you'll first have a period where doctors observe your health without any new medicine. Then, you'll start receiving the study medicine, mRNA-3927, for a set period. Throughout this treatment phase, doctors will closely monitor your health, take measurements, and perform tests to see how you're responding to the medicine and if you're experiencing any side effects. After the treatment period ends, there will be a follow-up period to ensure your health remains stable after stopping the medicine. The total number of hospital visits and the exact duration of each period will vary, but you can expect regular check-ups and assessments throughout the study.
Risques et avantages potentiels
Locations (35)
- UCSD Altman Clinical and Transalational Research Institute BuildingCode postal vérifiéLos Angeles, États-Unis· Pas encore en recrutement
- Ronald Reagan UCLA Medical CenterCode postal vérifiéLos Angeles, États-Unis· Recrutement
- Lucile Packard Children's Hospital StanfordCode postal vérifiéStanford, United States· Recrutement
- Nicklaus Children's HospitalCode postal vérifiéMiami, États-Unis· Pas encore en recrutement
- University of South Florida - 12901 Bruce B DownsCode postal vérifiéTampa, États-Unis· Pas encore en recrutement
- Ann and Robert H Lurie Childrens Hospital of ChicagoCode postal vérifiéChicago, États-Unis· Recrutement
- Johns Hopkins Hospital, Adult Outpatient Clinical Research UnitCode postal vérifiéBaltimore, États-Unis· Terminé
- Boston Children's HospitalCode postal vérifiéBoston, États-Unis· Terminé
- University of Michigan HospitalsCode postal vérifiéAnn Arbor, États-Unis· Recrutement
- Icahn School of Medicine at Mount Sinai - Clinical Research UnitCode postal vérifiéNew York, États-Unis· Recrutement
- Duke University Medical System (Duke Health)Code postal vérifiéDurham, États-Unis· Recrutement
- Cincinnati Children's Hospital Medical CenterCode postal vérifiéCincinnati, United States· Terminé
Questions fréquentes
What is Propionic Acidemia?
Propionic Acidemia (PA) is a rare inherited condition where the body can't properly process certain proteins and fats, leading to harmful substances building up in the blood.
What is mRNA-3927?
mRNA-3927 is a new experimental medicine being tested in this study to see if it can help treat Propionic Acidemia.
Qui peut participer à cette étude ?
The study is for people with a confirmed diagnosis of Propionic Acidemia, including children aged one year and older, and infants under one year, who meet specific health criteria.
What does a 'Phase 1/2' study mean?
This means the study is in its early stages. Phase 1 focuses on finding a safe dose and understanding how the medicine works, while Phase 2 further evaluates its effectiveness and safety in a larger group.
Will I receive the new medicine if I join?
Yes, if you meet the study criteria and are enrolled, you will receive the investigational medicine, mRNA-3927, according to the study plan.
Comment en savoir plus
Moderna WeCare Team
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.